Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Compound in dairy products targets diabetes
According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials.
- Compound in dairy products targets diabetes
According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials.
- Compound in dairy products targets diabetes
According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials.
- Compound in dairy products targets diabetes
According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials.
- Compound in dairy products targets diabetes
According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Study: Astaxanthin Prevents the Onset Of Asthenopia
Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group.
- Study: Astaxanthin Prevents the Onset Of Asthenopia
Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group.
- Study: Astaxanthin Prevents the Onset Of Asthenopia
Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group.
- Study: Astaxanthin Prevents the Onset Of Asthenopia
Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group.
- Study: Astaxanthin Prevents the Onset Of Asthenopia
Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group.
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
LIBERTY CORNER, N.J., Aug. 17 /PRNewswire/ -- Reliant Pharmaceuticals today announced the publication of new data in the July edition of the Journal of Clinical Pharmacology finding the co-administration of Omacor (omega-3-acid ethyl esters) with simvastatin has minimal interaction between the two drugs. Omacor (4 g) plus simvastatin (80 mg) did not significantly affect the steady-state pharmacokinetics of simvastatin and was well-tolerated in healthy patients.(1)
Omacor is the first and only Food and Drug Administration (FDA)-approved omega-3 fatty acid. Omacor was approved by the FDA in November 2004 as an adjunct to diet to reduce very high triglyceride levels (greater than or equal to 500 mg/dL) in adult patients.(2) At that time, Reliant Pharmaceuticals also received an FDA New Drug Application (NDA) approvable letter for Omacor in combination with a statin to treat high triglyceride levels (200-499 mg/dL) in adult patients. To gain final approval, Reliant is conducting a clinical trial to evaluate the efficacy and safety of Omacor as adjunctive therapy to simvastatin for the treatment of high triglycerides.(3)
"Many Americans who receive statin therapy continue to have elevated triglycerides. It's important to evaluate the safety and efficacy of Omacor as adjunctive therapy in these patients," said Robert Shalwitz, MD, Vice President of Clinical Development, Reliant Pharmaceuticals. "Reliant Pharmaceuticals is committed to patient safety and ongoing research for the effective use of Omacor."
About the Study
The open-label, randomized, 2-way crossover, drug-drug interaction study evaluated the impact of Omacor capsules on plasma simvastatin pharmacokinetics in 24 healthy patients. Patients were given 4 g of Omacor co-administered with 80 mg of simvastatin or 80 mg of simvastatin alone.(4) The primary pharmacokinetic end points for the determination of drug interaction were AUC (area under the plasma concentration-time curve over the final 0-24 hour dosing interval) and C(max) (maximum plasma concentration over the final dosing interval) on day 14.(5)
After 14 days of dosing, both the extent and rate of exposure to simvastatin and its major active metabolite, beta-hydroxy simvastatin, were similar after co-administration of Omacor and simvastatin compared with administration of simvastatin alone. Additionally, after single-dose administration, rates of exposure (C(max)) following either treatment were similar for both simvastatin and its beta-hydroxy metabolite. With single dosing, the AUC of simvastatin, but not that of its beta-hydroxy metabolite, increased (by 19% for AUC(0-t) and 24% for AUC(inf)) when Omacor and simvastatin were co-administered.(6)
Important Information About Omacor
* Omacor is used along with diet to reduce very high triglycerides in
adult patients. Before taking Omacor your healthcare provider should
help you try to control your high triglyceride level by:
-- Exercising and losing weight if you are overweight.
-- Decreasing alcohol use.
-- Controlling medical problems that can cause high triglyceride
levels (such as diabetes mellitus and hypothyroidism).
-- Stopping or changing medicines that can increase triglyceride
levels (such as estrogens, thiazide diuretics, beta blockers).
* Omacor should be used with caution in people allergic to fish.
Treatment to reduce very high triglyceride levels may result in
elevations in LDL-C and non-HDL-C in some individuals. The effect of
Omacor on cardiovascular morbidity and mortality in patients with very
high triglyceride levels has not been determined.
* Tell your healthcare provider about all your medical conditions,
including if you have liver problems, are pregnant, are trying to
become pregnant or are breast-feeding. Tell your healthcare provider
if you take blood thinners. If you take both Omacor and a blood
thinner, your healthcare provider should check you occasionally to see
if an effect has occurred.
* Some possible side effects of Omacor include belching, infection, flu
symptoms, upset stomach, rash and change in your sense of taste. This
is not a complete list Omacor side effects.
* For more detailed information about Omacor, ask your healthcare
provider or go to http://www.omacorrx.com.
About Reliant Pharmaceuticals
Reliant Pharmaceuticals is a pharmaceutical company with integrated sales, marketing and development expertise that markets a portfolio of branded cardiovascular pharmaceutical products. Reliant focuses on marketing promotionally sensitive pharmaceutical products to the high prescribing primary care, cardiovascular and specialist physician markets in the United States. Reliant also acquires rights to and develops product candidates in mid- to late-stage clinical development. Reliant's sales force infrastructure is comprised of approximately 850 sales professionals nationwide.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.
References:
(1) McKenney J, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling
D, Shalwitz R. Study of the Pharmacokinetic Interaction Between
Simvastatin and Prescription Omega-3-Acid Ethyl Esters. J Clin
Pharmacol. 2006; 46:785-791.
(2) OMACOR Prescribing Information, Liberty Corner, NJ: Reliant
Pharmaceuticals, Inc.; 2005.
(3) Data on file. Reliant Pharmaceuticals, Inc.
(4) McKenney J, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling
D, Shalwitz R. Study of the Pharmacokinetic Interaction Between
Simvastatin and Prescription Omega-3-Acid Ethyl Esters. J Clin
Pharmacol. 2006; 46:785-791.
(5) Ibid
(6) Ibid |